Sigrid V. Carlsson, MD, PhD, MPH

Sigrid V. Carlsson, MD, PhD, MPH

DKFZ German Cancer Research Center

Heidelberg, Germany

Sigrid V. Carlsson, MD, PhD, MPH, is the Division Head of the Clinical Epidemiology of Early Cancer Detection at DKFZ German Cancer Research Center in Heidelberg, Germany. Her research focuses on developing risk-stratified approaches to screening, diagnosis, treatment, and follow-up. 

Dr. Carlsson earned her MD and PhD from Gothenburg University in Sweden. She earned an MPH from Harvard in Boston, Massachusetts. Dr. Carlsson has been funded by the Prevent Cancer Foundation to develop a decision support tool for prostate cancer screening. She holds a career development award from the National Institutes of Health/National Cancer Institute, mentored by Drs. Jennifer Hay and Jada Hamilton, to optimize the practical application of shared decision-making and implementing risk-stratified approaches to screening and follow-up in oncology.

Dr. Carlsson serves on the National Comprehensive Cancer Network (NCCN) and is a panel member for the American Urological Association (AUA) guidelines for early detection of prostate cancer. She has authored and co-authored over 300 publications and has been featured in Société Internationale d’Urologie Journal, The Journal of Urology, European Urology, Clinical Chemistry, Urologic Oncology Seminars and Original Investigations, and more.

Talks by Sigrid V. Carlsson, MD, PhD, MPH

Year in Review: Emerging Data and Advances in Prostate Cancer Screening

Year in Review: Emerging Data and Advances in Prostate Cancer Screening

| Dec 2024

Sigrid Carlsson, MD, PhD, MPH, reviews groundbreaking advancements in prostate cancer screening and data from the past year. In this 9-minute presentation, Carlsson highlights the Swedish Berg trial, which showed a 30% reduction in prostate cancer mortality with regular PSA screening, while data from the UK CAP trial confirm that even a single PSA test reduces mortality. She stresses the utility of PSA as the strongest prognostic marker for lethal prostate cancer, with guidelines evolving to recommend tailored screening for high-risk groups like Black men.

Carlsson also shares that advances in MRI have proven pivotal. She references recent trials that underscore the efficacy of MRI-targeted biopsy in minimizing overdiagnosis. Innovations in AI for MRI interpretation promise to improve equity and diagnostic accuracy.

Dr. Carlssson shares that active surveillance is the standard for managing low-risk cancers and addressing concerns about overdiagnosis. Together, these developments mark a transformative year in personalized and effective prostate cancer screening.

Read More